v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating Expenses:    
Research and development $ 257,545 $ 724,742
Research and development - related party 61,667 25,000
General and administrative 414,120 421,290
Total Operating Expenses 733,332 1,171,032
Loss From Operations (733,332) (1,171,032)
Other (Expense) Income:    
Interest expense (76,483) (76,867)
Interest expense - related parties (11,166) (740)
Amortization of debt discount (8,302)
Change in fair value of derivative liabilities 16,977 52,600
Loss on extinguishment of debt (1,441)
Loss on exchange of notes payable for Series A Convertible Preferred Stock (262,470)
Total Other Expense (80,415) (287,477)
Net Loss (813,747) (1,458,509)
Dividend attributable to Series A preferred stockholders (211,305) (148,035)
Net Loss Applicable to Common Stockholders $ (1,025,052) $ (1,606,544)
Net Loss Per Common Share - Basic and Diluted $ (0.04) $ (0.06)
Weighted Average Common Shares Outstanding - Basic and Diluted 29,120,597 28,121,446

Source